Intravitreal Injection of Ultevursen

Phase 2RNA therapy

Intravitreal Injection of Ultevursen is one of 3 small molecule programs targeting Retinitis Pigmentosa (RP). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinitis Pigmentosa (RP)Active, not recruiting

Retinitis Pigmentosa (RP)Phase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Retinitis Pigmentosa (RP)

#DrugCompanyPhaseTrials

N-Acetylcysteine Amide

NNacuity Pharmaceuticals, Inc.

Phase 3

1 2

NPI-001

NNacuity Pharmaceuticals, Inc.

Phase 3

1 3

Intravitreal Injection of Ultevursen

LLaboratoires Thea

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Retinitis Pigmentosa (RP)

NCT06627179

Q1 2030

Phase 2Not yet recruiting

Retinitis Pigmentosa (RP)

NCT07796646

Clinical

Trials by Indication[1]

Retinitis Pigmentosa (RP)2 trials

An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Not yet recruiting·LLaboratoires Thea·Phase 2·NCT07796646·81 enrolled

A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Active, not recruiting·LLaboratoires Thea·Phase 2·NCT06627179·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Intravitreal Injection of Ultevursen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravitreal Injection of Ultevursen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravitreal Injection of Ultevursen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Laboratoires Thea company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 2[1]
Company: LLaboratoires Thea

Intravitreal Injection of Ultevursen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q1 2030

Trials by Indication[1]

Retinitis Pigmentosa (RP)2 trials

References

Drug Info

Quick Facts

Related News